{
  "source": "PA-Notification-Aqneursa.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1461-2\nProgram Prior Authorization/Notification\nMedication Aqneursa™ (levacetylleucine)\nP&T Approval Date 11/2024, 1/2025\nEffective Date 4/1/2025\n1. Background:\nAqneursa (levacetylleucine) is indicated for the treatment of neurological manifestations of\nNiemann-Pick disease type C (NPC) in adults and pediatric patients weighing ≥15 kg.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Aqneursa will be approved based on all of the following criteria:\na. Diagnosis of Niemann-Pick disease type C (NPC)\n-AND-\nb. Aqneursa is being used to treat neurological manifestations of NPC\n-AND-\nc. Patient is not receiving Aqneursa in combination with Miplyffa (arimoclomol)\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Aqneursa will be approved based on both the following criteria:\na. Documentation of positive clinical response to Aqneursa (e.g., slowed disease\nprogression from baseline based on assessment with NPC–specific scales)\n-AND-\nb. Patient is not receiving Aqneursa in combination with Miplyffa (arimoclomol)\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n© 2025 UnitedHealthcare Services Inc.\n1\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Aqneursa [package insert]. Austin TX: IntraBio Inc.; September 2024.\nProgram Prior Authorization/Notification - Aqneursa (levacetylleucine)\nChange Control\nDate Change\n11/2024 New program.\n1/2025 Added criteria that Aqneursa not ta",
    "tin TX: IntraBio Inc.; September 2024.\nProgram Prior Authorization/Notification - Aqneursa (levacetylleucine)\nChange Control\nDate Change\n11/2024 New program.\n1/2025 Added criteria that Aqneursa not taken in combination with Miplyffa.\n© 2025 UnitedHealthcare Services Inc.\n2"
  ]
}